CD274 and neoplasm: Additionally, the number of patients eligible for immune checkpoint inhibitor therapy depends on programmed cell death-ligand 1 expression levels in tumour-infiltrating lymphocytes, with an assumed calculated mean of 37% representing the range of 21% to 53%, as reported in studies [23,24] (Table 6).